Jupiter Neurosciences Doses First Patient in Parkinson's Phase 2a Trial, Explores Strategic Options
Jupiter Neurosciences has dosed the first patient in its Phase 2a RESET trial evaluating JOTROL™ for Parkinson's disease. The company has also retained Tungsten Advisors to explore strategic options to maximize shareholder value.